Is Osimertinib/Tagressa a domestic drug or an imported drug?

Osimertinib/Tagrisso (Osimertinib) is a highly efficient and selective EGFR mutant inhibitor, mainly used to treat non-small cell advanced lung cancer. Osimertinib does not originate in China, but is developed and produced by AstraZeneca AB in the UK. AstraZeneca is a multinational pharmaceutical company headquartered in London, England, which markets osimertinib globally. Therefore, the original osimertinib drug marketed in China is an imported drug.

Osimertinib is a multi-target targeted drug, mainly used for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation. In addition, it can also be used for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed during or after previous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment and whose EGFR T790M mutation-positive disease has been confirmed by testing.

Although osimertinib is an imported drug marketed in China, its efficacy and safety have been widely recognized. As for the domestic version of osimertinib, it has not appeared in the Chinese market. Although many pharmaceutical companies in China are working hard to develop and produce similar drugs, as of now, no domestic drug can completely replace osimertinib. At present, the original drug Osimertinib has been included in the scope of medical insurance. The common specifications are 80mg*30 tablets and 40mg*30 tablets. The price is about 4,000 to 6,000 yuan per box. In addition, prices may fluctuate over time and as market demand changes.